Alpha-1 Adrenergic Antagonists Induced Severe Rhinitis in Patients with Benign Prostatic HyperplasiaSHAHAR, Eduardo; NASSAR, Laila; KEDEM, Eynat et al.Current drug safety (Print). 2014, Vol 9, Num 2, pp 159-160, issn 1574-8863, 2 p.Article

Alfuzosin to Relieve Ureteral Stent Discomfort : A Prospective, Randomized, Placebo Controlled StudyBEDDINGFIELD, Richard; PEDRO, Renato N; HINCK, Bryan et al.The Journal of urology. 2009, Vol 181, Num 1, pp 170-176, issn 0022-5347, 7 p.Article

The Effects of Tolterodine Extended Release and Alfuzosin for the Treatment of Double-J Stent―Related SymptomsSEUNG CHOL PARK; SUNG WON JUNG; JEA WHAN LEE et al.Journal of endourology. 2009, Vol 23, Num 11, pp 1913-1917, issn 0892-7790, 5 p.Article

Highly sensitive and rapid LC-ESI-MS/MS method for the simultaneous quantification of uroselective α₁-blocker, alfuzosin and an antimuscarinic agent, solifenacin in human plasmaMISTRI, Hiren N; JANGID, Arvind G; PUDAGE, Ashutosh et al.Journal of chromatography. B. 2008, Vol 876, Num 2, pp 236-244, issn 1570-0232, 9 p.Article

BPH progression : concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONEROEHRBORN, Claus G.BJU international. Supplement (Print). 2008, Vol 101, Num 3, pp 17-21, issn 1465-5101, 5 p.Article

Effects of alfuzosin 10 mg once daily on sexual function in men treated for symptomatic benign prostatic hyperplasiaROSEN, R; SEFTEL, A; ROEHRBORN, C. G et al.International journal of impotence research. 2007, Vol 19, Num 5, pp 480-485, issn 0955-9930, 6 p.Article

In Vitro Controlled Release of Alfuzosin Hydrochloride Using HPMC-Based Matrix Tablets and Its Comparison with Marketed ProductNAIR, Anroop; GUPTA, Rachna; VASANTI, Sutrave et al.Pharmaceutical development and technology. 2007, Vol 12, Num 6, pp 621-625, issn 1083-7450, 5 p.Article

Alfuzosin (10 mg) does not affect blood pressure in young healthy men. CommentaryMONDAINI, Nicola; GIUBILEI, Gianluca; GRATZKE, Christian et al.European urology. 2006, Vol 50, Num 6, pp 1292-1298, issn 0302-2838, 7 p.Article

Comparison of the cardiovascular effects of tamsulosin oral controlled absorption system (OCAS®) and alfuzosin prolonged release (XL). CommentaryMICHEL, Martin C; CHAPPLE, Christopher R; FICARRA, Vincenzo et al.European urology. 2006, Vol 49, Num 3, pp 501-509, issn 0302-2838, 9 p.Article

Hemodynamic interaction study between the alpha₁-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjectsGIULIANO, Francois; KAPLAN, Steven A; CABANIS, Marie-Josée et al.Urology (Ridgewood, NJ). 2006, Vol 67, Num 6, pp 1199-1204, issn 0090-4295, 6 p.Article

The beneficial effect of alfuzosin 10 mg once daily in 'real-life' practice on lower urinary tract symptoms (LUTS), quality of life and sexual dysfunction in men with LUTS and painful ejaculationNICKEL, J. Curtis; ELHILALI, Mostafa; EMBERTON, Mark et al.BJU international (Papier). 2006, Vol 97, Num 6, pp 1242-1246, issn 1464-4096, 5 p.Article

The management of acute urinary retention in France : a cross-sectional survey in 2618 men with benign prostatic hyperplasiaDESGRANDCHAMPS, Francois; DE LA TAILLE, Alexandre; DOUBLET, Jean-Dominique et al.BJU international (Papier). 2006, Vol 97, Num 4, pp 727-733, issn 1464-4096, 7 p.Article

The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK : a 6-month analysisANNEMANS, Lieven; CLEEMPUT, Irina; LAMOTTE, Mark et al.BJU international (Papier). 2005, Vol 96, Num 4, pp 566-571, issn 1464-4096, 6 p.Article

Clinical and pressure-flow changes after long-term treatment with alfuzosin SRDE NUNZIO, C; FRANCO, G; LORI, F et al.Urologia Internationalis. 2003, Vol 71, Num 1, pp 31-36, issn 0042-1138, 6 p.Article

Worldwide experience with alfuzosin and tamsulosinMICHEL, Martin C; FLANNERY, Michael T; NARAYAN, Perinchery et al.Urology (Ridgewood, NJ). 2001, Vol 58, Num 4, pp 508-516, issn 0090-4295Article

Effects of short-term treatment with the α₁-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasiaMARTORANA, G; GIBERTI, C; DI SILVERIO, F et al.European urology. 1997, Vol 32, Num 1, pp 47-53, issn 0302-2838Article

Comparison of core-shell and totally porous ultra high performance liquid chromatographic stationary phases based on their selectivity towards alfuzosin compoundsSZULFER, Jarosław; PLENIS, Alina; BACZEK, Tomasz et al.Journal of chromatography. 2014, Vol 1346, pp 69-77, issn 0021-9673, 9 p.Conference Paper

Phosphodiesterase Type 5 Inhibitors in the Management of Non-neurogenic Male Lower Urinary Tract Symptoms: Critical Analysis of Current EvidenceMARTINEZ-SALAMANCA, Juan I; CARBALLIDO, Joaquin; EARDLEY, Ian et al.European urology. 2011, Vol 60, Num 3, pp 527-535, issn 0302-2838, 9 p.Article

Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia : a 3-year experience in real-life practiceVALLANCIEN, Guy; EMBERTON, Mark; ALCARAZ, Antonio et al.BJU international (Papier). 2008, Vol 101, Num 7, pp 847-852, issn 1464-4096, 6 p.Article

Intraoperative Floppy Iris Syndrome Associated with α_I-Adrenergic Receptor AntagonistsCANTRELL, Matthew A; BREAM-ROUWENHORST, Heather R; STEFFENSMEIER, Andrew et al.The Annals of pharmacotherapy. 2008, Vol 42, Num 4, pp 558-563, issn 1060-0280, 6 p.Article

The influence of alpha₁ -adrenoreceptors on neuropeptide release from primary sensory neurons of the lower urinary tractTREUISANI, Marcello; CAMPI, Barbara; GATTI, Raffaele et al.European urology. 2007, Vol 52, Num 3, pp 901-908, issn 0302-2838, 8 p.Article

On-line solid-phase extraction with a monolithic weak cation-exchange column and simultaneous screening of α1-adrenergic receptor antagonists in human plasmaXIAOYI WEI; JUNFA YIN; GENGLIANG YANG et al.Journal of separation science. 2007, Vol 30, Num 17, pp 2851-2857, issn 1615-9306, 7 p.Article

Toxic epidermal necrolysis caused by alfuzosin, an α₁-adrenoceptor antagonist. CommentaryWANG, Yi-Shi; TAY, Yong-Kwang; KWOK, Colin et al.Archives of dermatology (1960). 2006, Vol 142, Num 7, pp 938-938, issn 0003-987X, 1 p.Article

Combination of phosphodiesterase-5 inhibitors and α-blockers in patients with benign prostatic hyperplasia : treatments of lower urinary tract symptoms, erectile dysfunction, or both?CARSON, Culley C.BJU international (Papier). 2006, Vol 97, pp 39-43, issn 1464-4096, 5 p., SUP2Article

Manaqement of acute urinary retentionFITZPATRICK, John M; KIRBY, Roger S.BJU international. Supplement (Print). 2006, Vol 97, Num 2, pp 16-20, issn 1465-5101, 5 p.Article